Chronic myeloproliferative neoplasms

The -2518 A/G polymorphism of the monocyte chemoattractant protein-1 as a candidate genetic predisposition factor for secondary myelofibrosis and biomarker of disease severity

Elena Masselli1 · Cecilia Carubbi1 · Benedetta Cambó2 · Giulia Pozzi1 · Giuliana Gobbi1 · Prisco Mirandola1 · Elena Follini2 · Luca Pagliaro2 · Daniela Di Marcantonio3 · Francesco Bonatti4 · Antonio Percesepe4 · Stephen M. Sykes3 · Franco Aversa2 · Marco Vitale1,5

Philadelphia-negative myeloproliferative neoplasms (MPN), namely polycythemia vera (PV), essential thrombocythemia (ET) and myelofibrosis (MF), are closely-related stem cell disorders, characterized by abnormal proliferation and differentiation of hematopoietic progenitors [1, 2]. Transitions between disease entities are common, shaping a “biological continuum” from an early stage with a relatively milder phenotype (PV and ET) toward an advanced phase, termed secondary myelofibrosis (sMF) [3]. Similarly, pre-fibrotic and overt primary myelofibrosis (pre-PMF and overt-PMF, respectively), according to the 2016 WHO criteria [4] have been shown to be aligned along a phenotypic gradient of severity [5]. Although different biomarkers have been associated with MPN thrombotic comorbidities [6, 7], no known parameters for predicting whether PV or ET will advance to sMF or for establishing a timeline for the progression of pre-PMF into overt disease currently exist.

Chronic inflammation plays a pivotal role in MPN pathogenesis, triggering neoplastic transformation and catalyzing clonal evolution toward end-stage disease. Indeed, MPN cells release a plethora of pro-inflammatory products, which in turn elicits genomic instability and drive clonal myeloproliferation [3, 8]. It has been demonstrated that: (i) MF patients display higher circulating levels of several pro-inflammatory cytokines as compared to other chronic myeloproliferative disorders as well as to healthy subjects [9], with IL-8, IL-2R, IL-12 and IL-15 levels independently holding prognostic value [10]; (ii) MCP-1 (monocyte chemoattractant protein-1, also known as CCL2), soluble IL-2R and IL-15 levels cluster with splenomegaly [11]; (iii) MCP-1 levels correlate with lower anemia response to pomalidomide [11].

MCP-1 is the main chemotactic factor for monocyte migration in sites of inflammation and contributes to organ fibrotic changes [12]. MCP-1 expression levels are highly variable among individuals, potentially contributing to differential susceptibility to various inflammatory conditions [13]. An A to G single-nucleotide polymorphism (SNP) in MCP-1 enhancer region (rs1024611, originally designated as –2518 G or –2578 G) was found to be responsible for higher levels of MCP-1 production by monocytes upon inflammatory noxa [14], and has been associated to several chronic inflammatory conditions such as autoimmune disorders, atherosclerosis and chronic infectious diseases [15].

In the present study, we investigated whether the -2518 A/G SNP of MCP-1 is a potential indicator of MPN susceptibility and/or disease phenotype.

After approval by the local ethical committee (prot. n 27182) and written informed consent, n 177 Caucasian MPN patients were recruited, of which n 44 PV, n 65 ET, n 68 MF (n 45 PMF and n 23 sMF). For PMF patients,
histopathology, clinical and laboratory data were reviewed and diagnoses attributed to pre-PMF (n 12) or overt-PMF (n 33) according to the revised 2016 WHO criteria [4]. DNA was extracted by PureLink® Genomic DNA Kit (Invitrogen) from 200 µl of whole blood and from buccal mucosa cells following manufacturer’s instructions. DNA from 149 age-matched and sex-matched Caucasian healthy subjects (CTRL) was provided by the Unit of Medical Genetics, University Hospital of Parma. Patients and CTRL genotyping was performed by TaqMan® Predesigned SNP Genotyping Assays (Applied Biosystems). Patients’ data were retrospectively analyzed from cataloged hospital records.

For statistical analysis, numerical variables were summarized by their median and range, and categorical variables by count and relative frequency (percentage). Differences in the distribution of continuous variables were calculated by Mann–Whitney/Kruskal–Wallis tests, while categorical variable comparison were established by χ²/Fisher exact test. A P value <0.05 was considered statistically significant. Analysis was performed with dedicated software (Epi Info 7.2.1.0; CDC, Atlanta, GA, USA or StatView 5.0; SAS Institute Inc, Cary, NC, USA).

Case and control groups were aligned for age and gender distribution. Clinical and biological characteristics of MPN patients and CTRL are summarized in Supplemental Table 1. Genotypic and allelic frequencies of the MCP-1 -2518 A/G SNP in overall MPN population, PV, ET, MF patients and CTRL were summarized in Supplemental Table 1.

Genotypic and allelic frequencies of the -2518 A/G SNP of MCP-1 in overall MPN population, PV, ET, MF patients and CTRL are reported in Table 1. Genotypic frequencies were in Hardy–Weinberg equilibrium both in the MPN patients and CTRL (P > 0.05). No statistical differences were found by comparing genotypic and allelic frequencies of overall MPN, PV, ET and MF patients vs. CTRL, as well as between single disease entities.

Focusing on MF, which is the MPN variant characterized by the highest inflammation burden [16], we evaluated whether polymorphic genotypes could be associated to specific disease subtype(s) (based on the 2016 WHO criteria) or to disease phenotype aggressiveness based on the hematologic characteristics at the time of diagnosis (Table 2).

We found that the subjects carrying either a heterozygous or homozygous genotype for the -2518 A/G SNP (A/G + G/G) were significantly more frequent in sMF vs. PMF (17/23, 73.9% vs. 14/45, 31.1%, respectively, P = 0.0008, Table 2). Additionally, sMF was significantly more frequent in A/G + G/G patients than either pre-PMF (1/12, 8.3%, P = 0.0002) or overt-PMF (13/33, 39.4%, P = 0.011). Notably, the number of A/G + G/G subjects was also significantly higher in sMF as compared to CTRL (P = 0.022) (Table 2).

The observation that sMF is enriched in allele-G carriers is consistent with the concept of myelofibrosis as a burn-out phase of a long process that starts with ET/PV and advances toward a more progressive disease state, characterized by higher inflammation burden [3, 16].

Genotype–phenotype correlation studies in MF patients revealed a higher frequency of allele-G carriers (A/G + G/G) in: (i) intermediate-2/high vs. low/intermediate-1 IPSS risk group (15/22, 68.2% vs. 14/42, 33.3%, respectively, P = 0.0078), (ii) patients with lower (Hb < 100 g/L) vs. higher (Hb ≥ 100 g/dL) hemoglobin levels (9/13, 69.2% vs. 18/49, 36.7%, P = 0.036), (iii) patients with (<1%) vs. patients without (<1%) circulating blasts (8/10, 80%, vs. 20/53, 37.4%, P = 0.014), (iv) patients with higher (≥II) vs. lower (0–I) grading of bone marrow fibrosis (20/36, 55.6% vs. 9/29, 31.0%, P = 0.048) (Table 2).

No associations with age, gender, white blood cell and platelet count, LDH levels, presence of constitutional symptoms, spleen size, JAK2V617F mutation, and history of major thrombotic events were found (Table 2).

Finally, to evaluate whether the MCP-1 -2518 A/G SNP is inherited or acquired by hematopoietic stem cells, we tested the SNP in non-clonal cells of 14 MPN patients (10 MF, 3 ET and 1 PV) harboring the G allele, as assessed by whole blood genotyping. The analysis of buccal mucosal cells revealed that all individuals were germline carriers of the polymorphism.

In conclusion, our data suggest that the -2518 A/G SNP of MCP-1 could represent a host genetic predisposition factor for sMF and may serve as a biomarker of disease severity in MF, as implied by its association with higher inflammation burden.
| Disease type       | No. of cases | A/A       | A/G + G/G | P [O.R., 95% C.I.] |
|-------------------|--------------|-----------|-----------|--------------------|
| PMF, n (%)        | 45           | 31 (68.9) | 14 (31.1) | *P = 0.0008 vs. sMF* [6.23; 2.04–19.32] |
| Pre-PMF, n (%)    | 12           | 11 (91.7) | 1 (8.3)   | *P = 0.0002 vs. sMF* [31.17: 3.29–295.35] |
| Overt-PMF, n (%)  | 33           | 20 (60.6) | 13 (39.4) | *P = 0.011 vs. sMF* [4.36; 1.36–13.95] |
| sMF n (%)         | 23           | 6 (26.1)  | 17 (73.9) | *P = 0.022 vs. CTRL* [3.07; 1.14–8.32] |

| Age               | Median (range), years | 68 | 69.0 (29–84) | 70.0 (30–86) | *P = 0.61* |
|-------------------|-----------------------|----|--------------|--------------|------------|
| >65 years, n (%)  | 46                    |    | 25 (54.4)    | 21 (45.6)    | *P = 0.99* |

| Gender            | Male, n (%)           | 41 | 21 (51.2)    | 20 (48.8)    | *P = 0.51* |
|-------------------|-----------------------|----|--------------|--------------|------------|
| Female, n (%)     | 27                    |    | 16 (59.3)    | 11 (40.7)    |            |

| IPSS              | Low/intermediate-1, n (%) | 42 | 28 (66.7)    | 14 (33.3)    | *P = 0.0078* [4.29; 1.42–12.91] |
|-------------------|---------------------------|----|--------------|--------------|------------|
| Intermediate-2/high, n (%) | 22                | 7  | 31.8         | 15 (68.2)    |            |

| Hemoglobin        | Median (range), g/L      | 62 | 12.7 (5–15.9) | 11.7 (7.3–15.5) | *P = 0.062* |
|-------------------|--------------------------|----|--------------|--------------|------------|
| <100 g/L, n (%)   | 13                      | 4  | 30.8         | 9 (69.2)     | *P = 0.036* [3.89; 1.04–14.41] |

| WBC               | Median (range), x10^9/L | 62 | 9.2 (3.9–57.8) | 12.1 (2.9–57.0) | *P = 0.78* |
|-------------------|-------------------------|----|--------------|--------------|------------|
| <4 × 10^9/L or >25 × 10^9/L, n (%) | 7             | 3  | 42.9         | 4 (57.1%)    | *P = 0.44* |

| Platelets         | Median (range), x10^9/L | 60 | 560 (99–1322) | 376 (69–984) | *P = 0.10* |

| LDH               | Median (range), U/L     | 59 | 622 (205–1620) | 751 (343–1580) | *P = 0.22* |
|-------------------|-------------------------|----|--------------|--------------|------------|
| >Normal range, n (%) | 47                | 26 | 55.3         | 21 (44.7)    | *P = 0.85* |

| Constitutional symptoms | Yes, n (%) | 47 | 7 (41.8) | 10 (58.8) | *P = 0.19* |
|-------------------------|------------|----|---------|----------|------------|
| No, n (%)               | 17         | 28 | 59.6    | 19 (40.4) |            |

| Circulating blasts     | <1%, n (%)  | 53 | 33 (62.3) | 20 (37.4) | *P = 0.014* [6.6; 1.27–34.23] |
|-----------------------|-------------|----|---------|----------|------------|
| ≥1%, n (%)            | 10          | 2  | 20.0    | 8 (80.0) |            |

| Grading of fibrosis   | 0–I, n (%)  | 29 | 20 (69.0) | 9 (31.0) | *P = 0.048* [2.78; 0.99–7.43] |
|-----------------------|-------------|----|---------|----------|------------|
| ≥II, n (%)            | 36          | 16 | 44.4    | 20 (55.6) |            |

| Spleen (long. Ø by US) | median (range), cm | 68 | 14.0 (7.5–30) | 17.0 (10–30) | *P = 0.1* |
|------------------------|--------------------|----|--------------|--------------|------------|

| JAK2V617F mutation     | Positive, n (%)    | 40 | 21 (52.5) | 19 (47.5) | *P = 0.44* |
|------------------------|--------------------|----|---------|----------|------------|
| Negative, n (%)        | 19                  | 12 | 63.2    | 7 (36.8) |            |

| Major thrombotic events | Yes, n (%) | 22 | 11 (50.0) | 11 (50.0) | *P = 0.55* |
|-------------------------|------------|----|---------|----------|------------|
| No, n (%)               | 45         | 26 | 57.8    | 19 (42.2) |            |

The -2518 A/G polymorphism of the monocyte chemoattractant protein-1 as a candidate genetic...
IPSS, peripheral blasts, lower hemoglobin and higher grading of bone marrow fibrosis. In particular, the association of the SNP with higher grading of bone marrow fibrosis as well as with severe anemia is consistent with the well-defined pro-fibrotic role of this chemokine [12] and the previously described observation that MCP-1 levels correlate with poor anemia response [11]. We speculate that this SNP, after prospective validation studies, may configure as a genetic biomarker identifying ET and PV patients who more likely will progress toward a spent phase.

Acknowledgements This work was supported by Regione Emilia-Romagna Area 1-Strategic Program 2010–2012 and Fondi Locali per la Ricerca 2014-Quota Incentivante-Università degli Studi di Parma. The authors are grateful to Prof. Nicola Giuliani, University of Parma, for instrumental support.

Author contributions E.M., C.C., M.V. designed the research and wrote the manuscript. E.M., C.C., G.P. performed the experiments and interpreted the data. P.M. G.G. interpreted the data and revised the manuscript. B.C., E.F., L.P., F.A. provided patients’ sample and data. F.B. and A.P. provided control samples and advised statistics. D.D.M. and S.M.S. advised research and statistics, revised the manuscript.

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Vainchenker W, Kralovics R. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. Blood. 2017;129:667–79.
2. Masselli E, Carubbi C, Gobbi G, Miranda P, Galli D, Martini S, et al. Protein kinase Cβ epsilon inhibition restores megakaryocytic differentiation of hematopoietic progenitors from primary myelofibrosis patients. Leukemia. 2015;29:2192–201.
3. Hasselbalch HC. Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development? Leuk Res. 2013;37:214–20.
4. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–405.
5. Guglielmelli P, Pacilli A, Rotunno G, Rumi E, Rosti V, Delaini F, et al. Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis. Blood. 2017;129:3227–36.
6. Barbui T, Falanga A. Molecular biomarkers of thrombosis in myeloproliferative neoplasms. Thromb Res. 2016;140(Suppl 1):S71–75.
7. Masselli E, Carubbi C, Pozzi G, Martini S, Aversa F, Galli D, et al. Platelet expression of PKC epsilon oncoprotein in myelofibrosis is associated with disease severity and thrombotic risk. Ann Transl Med. 2017;5:273–273.
8. Lussana F, Rambaldi A. Inflammation and myeloproliferative neoplasms. J Autoimmun. 2017;85:58–63.
9. Mondet J, Hussein K, Mossuz P. Circulating cytokine levels as markers of inflammation in Philadelphia negative myeloproliferative neoplasms: diagnostic and prognostic interest. Mediat Inflamm. 2015. 2015:2015:670580–10.
10. Tefferi A, Vaidya R, Caramazza D, Finke C, Lasho T, Pardanani A. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol. 2011;29:1356–63.
11. Pardanani A, Begna K, Finke C, Lasho T, Tefferi A. Circulating levels of MCP-1, sIL-2R, IL-15, and IL-8 predict anemia response to pomalidomide therapy in myelofibrosis. Am J Hematol. 2011;86:343–5.
12. Deshmukh SL, Kremlev S, Amini S, Sawaya BE. Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res. 2009;29:313–26.
13. Pham MH, Bonello GB, Castiblanco J, Le T, Sigala J, He W, et al. The rs1024611 regulatory region polymorphism is associated with CCL2 allelic expression imbalance. PLoS One. 2012;7:e49498.
14. Rovin BH, Lu L, Saxena R. A novel polymorphism in the MCP-1 gene regulatory region that influences MCP-1 expression. Biochem Biophys Res Commun. 1999;259:344–8.
15. Colbran R, Pujol-Borrell R, Armengol MP, Juan M. The chemokine network. II. On how polymorphisms and alternative splicing increase the number of molecular species and configure intricate patterns of disease susceptibility. Clin Exp Immunol. 2007;150:1–12.
16. Hasselbalch HC, Bjorn ME. MPNs as inflammatory diseases: the evidence, consequences, and perspectives. Mediat Inflamm. 2015. 2015:2015:102476–16.